Disease relapse after autologous hematopoietic transplant (auto-HCT) remains the number one cause of post-transplant therapy failure and mortality. The last decade has seen a proliferation of clinical studies looking at the prevention of post-auto-HCT therapy failure with various maintenance strategies. The benefit of such therapies is in turn dependent on disease histology and timing of transplantation. Although @entity34 ( @entity34 ) provides durable responses in chemosensitive relapsed @entity1892 ( @entity1892 ), a sizable subset experiences disease relapse. Unfortunately, the addition of rituximab as a post-auto-HCT maintenance strategy did not improve survival outcomes. The preliminary results with programmed death -1 (PD-1) Ab as post-auto maintenance in @entity1892 is promising but requires randomized validation. In @entity706 , the 5- and 10-year PFS rates are ~60% and 31%, respectively. Although the addition of rituximab improved PFS, there is no survival benefit, to date. Disease relapse after auto-HCT in @entity1073 ( @entity1073 ) is not uncommon. Rituximab maintenance in this setting provides a PFS benefit. Given the poor prognosis of @entity177 in @entity1073 , maintenance can be considered on a case-by-case basis. In chemosensitive relapsed @entity978 , addition of brentuximab vedotin after auto-HCT improved 2-year PFS (65 vs 45%) and can be considered as an option for maintenance therapy post auto-HCT, in select higher risk @entity1 . Ongoing trials evaluating the efficacy of post-auto-HCT maintenance with novel agents (for example, immunomodulators, proteasome inhibitors, PD-1 inhibitors, Bruton's @entity4149 kinase inhibitors and so on) will likely change the practice landscape for @entity706 @entity1 following @entity34 and auto-HCT.

Post-autologous transplant maintenance therapies in XXXX : are we there yet?

@entity1 :: ('9606', 'Species') :: ['patients'] @entity706 :: ('MESH:D008223', 'Disease') :: ['lymphoma', 'follicular lymphoma'] @entity177 :: ('MESH:D051437', 'Disease') :: ['post-auto-HCT failures'] @entity1892 :: ('MESH:D016393', 'Disease') :: ['DLBCL', 'diffuse large B-cell lymphoma'] @entity1073 :: ('MESH:D020522', 'Disease') :: ['mantle cell lymphoma', 'MCL'] @entity978 :: ('MESH:D006689', 'Disease') :: ['Hodgkin lymphoma'] @entity4149 :: ('D014443', 'Chemical') :: ['tyrosine'] @entity34 :: ('MESH:D016609', 'Disease') :: ['HDT', 'high dose therapy']
@entity706 :: (MESH:D008223,Disease) :: ['lymphoid malignancies']
